Lonnie Moulder,
President and
Chief Executive Officer of
MGI PHARMA, INC.
opened
The NASDAQ Stock Market

Monday, September 15, 2003
at NASDAQ's MarketSite
in New York City.

Click here for more information on

MGI PHARMA, INC.

Company Celebrates 20-Year Listing Anniversary

In celebration of being listed on the NASDAQ National Market for 20 years and in recognition of the recent FDA approval of Aloxi(TM), MGI PHARMA, INC. [MOGN] and its President and CEO Lonnie Moulder will open the market. Aloxi (palonosetron hydrochloride) injection was approved by the FDA on July 25, 2003 at a fixed dose of 0.25 mg for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy and for the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

About Aloxi(TM)

Aloxi is a selective 5-HT3 receptor antagonist with high receptor binding affinity and an extended 40-hour plasma half-life that was developed for the prevention of CINV. Results from phase 3 clinical trials demonstrate that a single IV dose of Aloxi is effective in preventing both acute and delayed CINV in patients receiving moderately emetogenic chemotherapy, the most common chemotherapy regimens used in the treatment of cancer. Aloxi is the first and only 5-HT3 receptor antagonist to be indicated for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) caused by moderately emetogenic cancer chemotherapy. Healthcare professionals and cancer patients in the United States can learn more about Aloxi by visiting www.aloxi.com.

About MGI PHARMA, INC. [MOGN]

MGI PHARMA, INC. is an oncology-focused biopharmaceutical company that acquires, develops and commercializes proprietary products that address the unmet needs of cancer patients. MGI markets Aloxi(TM) (palonosetron hydrochloride) injection, Salagen(R) Tablets (pilocarpine hydrochloride) and Hexalen(R) (altretamine) capsules in the United States. For more information about MGI, please visit the Company's Web site at www.mgipharma.com.